Vanda Pharmaceuticals Inc. (VNDA) Thursday said that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for VGT-1849B for the treatment of polycythemia vera (PV), a rare type of blood cancer.
The orphan drug designation provides certain benefits including tax credits for qualified clinical trials, exemption from user fees, and seven years of market exclusivity after approval.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.